2019 Hong Kong IPO Analytics: Highlight of Brokersā and Sectorsā Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
782 Views
Alphamab Oncology: Trading Debut, Valuation Scenario Analysis
Alphamab Co Ltd (9966 HK)Ā is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
606 Views
Alphamab (åŗ·å®ę°ē) IPO: Allocation and Buy-Level for the Hot Deal
Alphamab, the leading bispecific antibodies player in China, raised USD 220 million at HKD 10.2 per share. In this insight, we will cover the...
609 Views
ECM Weekly (8 Dec 2019) - OneConnect, JS Global, Renrui, Poly Property, Freee, Burger King India
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This...
602 Views
Alphamab Oncology IPO: Valuation Easy to Swallow
Alphamab Co Ltd (9966 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
623 Views